AcuCort signs its first commercial agreement for the company’s drug Zeqmelit™
LUND, Sweden, Nov. 24, 2022 /PRNewswire/ -- AcuCort AB (publ) (Spotlight Stock Market: ACUC) today announces that the company has signed an exclusive commercial agreement with the global biopharmaceutical company Kamada Ltd., (NASDAQ: KMDA; TASE: KMDA.TA). The agreement gives Kamada the exclusive right to the marketing and sales as well as the distribution of AcuCort's drug Zeqmelit™ for, among other...
Korea Ginseng Corp.: As an adaptogenic herb, Korean red ginseng boosts the human immune response
KORESELECT Immune receives the 2022 Taste For Life Immunity Essential award CERRITOS, Calif., Nov. 23, 2022 /PRNewswire/ -- Korean Ginseng Corp., the world's number one Korean red ginseng brand, is highlighting Korean red ginseng as another way to stay healthy. Korea Ginseng Corp.: As an adaptogenic herb, Korean red ginseng boosts the human...
AnchorDx Enrolls the First Patient For Its UriFind® Bladder Cancer Assay Clinical Trial in the U.S.
GUANGZHOU, China, Nov. 23, 2022 /PRNewswire/ -- AnchorDx, a world-leading developer of cancer early detection solutions, announced the first patient enrollment for the UriFind® bladder cancer assay clinical trial in the U.S., an over 1,000-patient multi-center, prospective testing of the assay in the targeted patients. This prospective, registrational study is aimed to...
Kinseed Selects Solace’s Event Streaming and Management Solution to Accelerate Digital Transformation in the Healthcare Industry
Leading healthcare IT provider revolutionizing the patient data journey with event-driven architecture LONDON, Nov. 23, 2022 /PRNewswire/ -- Solace, the leading enabler of event-driven architecture (EDA) for real-time enterprises, announced today that UK-based Kinseed is using Solace's event streaming and management solution, PubSub+ Platform, to improve and expand the real-time data distribution...
Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by U.S. FDA
--The Phase I clinical trial will consist of 3 cohorts in healthy subjects, including single- and multiple-dose escalation studies and food effect study. The objective of Phase I trial is to find a right dose to move into the pivotal Phase II/III in COVID-19 patients --In antiviral cellular assays with infectious SARS-CoV-2, ASC11 demonstrated much higher potency...
WuXi AppTec Begins Construction of Wuxi STA Pharmaceutical East China R&D Facility
The pharmaceutical leader also signs agreement on Phase V CRDMO Project CHANGZHOU, China, Nov. 22, 2022 /PRNewswire/ -- WuXi AppTec recently held the groundbreaking ceremony for its Wuxi STA Pharmaceutical East China R&D facility in tandem with the signing ceremony for the Phase V CRDMO Project in Changzhou National High-Tech District. WuXi AppTec Begins Construction of Wuxi STA...
J INTS BIO, M.D Anderson Cancer Center joint development – oral HSP90 inhibitor ‘JIN-001’, presentation of preclinical assessment at 2022 SNO Annual Meeting
SEOUL, South Korea, Nov. 23, 2022 /PRNewswire/ -- J INTS BIO announced that the preclinical assessment of JIN-001 or MPT0B640, a novel, orally administered 2nd generation HSP90 (heat shock protein 90) inhibitor, was presented during the 2022 edition of the Society for Neuro-Oncology Conference, held in Tampa, Florida from 17th to 20th November. J INTS BIO CI ...
Jiangsu Traditional Chinese Medicine International Exchange Conference kicked off in Nanjing
NANJING, China, Nov. 23, 2022 /PRNewswire/ -- On November 21st, the "Jiangsu Traditional Chinese Medicine International Exchange Conference" jointly sponsored by the Foreign Affairs Office of Jiangsu Provincial People's Government and Jiangsu Health Commission kicked off in Nanjing. The theme of the conference is "Let the World Know Jiangsu Traditional Chinese Medicine", according to the organizing committee. Hu...
Lunit Partners with CARPL.ai to Accelerate AI-Powered Medical Imaging Across Major Overseas Channels
Lunit signed a global distribution agreement to provide its AI-based radiology solutions for clinical use via CARPL.ai's platform The partnership will deliver Lunit INSIGHT CXR and Lunit INSIGHT MMG for commercial use in the U.S., Australia, Brazil, India, and Singapore SEOUL, South Korea, Nov. 23, 2022 /PRNewswire/ -- Lunit (KRX:...
PHISKIN Rolls Out Upgrade of Its One-stop High-end Medical Service System
SHANGHAI, Nov. 22, 2022 /PRNewswire/ -- PHISKIN, a Chinese aesthetic medicine clinics brand, has announced a new enhancement to its one-stop high-end medical service system as part of the expansion of its healthcare business. The firm was founded in Shanghai in 2012 and pioneered the era of aesthetic medicine in mainland China by introducing the concept of minimally invasive...
